What changed in the MIRM analyst rating on February 26, 2026?

On **February 26, 2026**, Leerink Partners, Evercore ISI, and RBC Capital all **maintained Outperform** on MIRM. Leerink lowered its price target to **$118**, while Evercore and RBC defended the stock amid a volatile pullback.

How should investors interpret the Leerink price target cut?

Leerink’s cut to **$118** with an unchanged Outperform suggests revised valuation timing or assumptions, not a lost thesis. The move signals caution on timing, while still backing Mirum’s longer term upside.

Does the maintained Outperform mean buy now?

Maintained Outperform is a positive analyst view, but not a direct buy signal. Combine the **MIRM analyst rating** with price action, catalysts, and your risk profile before acting.

How does Meyka AI view MIRM after these notes?

Meyka AI tracks the coverage and assigns MIRM a **B+** grade based on sector, growth, benchmarks, and analyst consensus. This reflects balanced upside potential and near-term risk but is not financial advice.

Analyst Ratings

MIRM Mirum Pharmaceuticals, Inc. Feb 26 2026 Leerink Maintains Outperform

ByHuzaifa Zahoor February 27, 2026February 27, 2026

Three major firms maintained Outperform on Mirum Pharmaceuticals, Inc. (MIRM) on February 26, 2026, keeping analyst conviction despite a sharp intraday drop. The phrase MIRM analyst rating frames this update: Leerink Partners, Evercore ISI, and RBC Capital each left their ratings unchanged while responding differently to the stock move. Leerink cut its price target to $118, while RBC and Evercore defended the pullback as noise and a buying opportunity. These actions drove a 13–15% retracement and matter for investors tracking consensus and price targets right now.